ImmunoPrecise Antibodies Ltd. Files October 2024 6-K Report

TL;DR

IPA files routine 6-K for October, CFO Kristin Taylor signed off.

AI Summary

ImmunoPrecise Antibodies Ltd. filed a Form 6-K on October 24, 2024, reporting for the month of October 2024. The filing was signed by Kristin Taylor, Chief Financial Officer, on October 23, 2024. The company is incorporated in A1 and has its principal executive offices in Victoria, British Columbia.

Why It Matters

This filing serves as an update for investors regarding the company's ongoing reporting requirements as a foreign private issuer. It confirms the company's adherence to regulatory disclosures.

Risk Assessment

Risk Level: low — This is a routine filing that does not contain new financial information or material events.

Key Players & Entities

• ImmunoPrecise Antibodies Ltd. (company) — Registrant
• Kristin Taylor (person) — Chief Financial Officer
• October 2024 (date) — Reporting period
• October 23, 2024 (date) — Signing date
• 001-39530 (other) — Commission File Number

FAQ

Filing Documents

• circular_november_2024.htm (6-K) — 939KB
• img197481037_0.jpg (GRAPHIC) — 90KB
• img197481037_1.jpg (GRAPHIC) — 112KB
• img197481037_2.jpg (GRAPHIC) — 82KB
• 0000950170-24-116728.txt ( ) — 1331KB

From the Filing

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October , 2024 . Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street , Victoria , British Columbia V8Z 7X (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: October 23, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer INCORPORATION BY REFERENCE Exhibit 99.2 of this Form 6-K is incorporated by reference into the Registrant’s Registration Statement on Form S-8 (File No. 333-256730) and the Registrant’s Registration Statements on Form F-3 (File Nos. 333-273197 and 333-281312 ). EXHIBIT INDEX Exhibit Description 99.1 Notice of Annual General Meeting of Shareholders dated October 14, 2024 99.2 Management Information Circular dated October 14, 2024 99.3 Form of Proxy IMMUNOPRECISE ANTIBODIES LTD. Unit 3204 – 4464 Markham Street Victoria, BC V8Z 7X8 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 14, 2024 AND INFORMATION CIRCULAR October 14, 2024 IMMUNOPRECISE ANTIBODIES LTD. Unit 3204 – 4464 Markham Street, Victoria, BC V8Z 7X8 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual general meeting (the “ Meeting ”) of the shareholders of ImmunoPrecise Antibodies Ltd. (the “ Company ”) will be held via live webcast at https://meetnow.global/MCLVFHX on Thursday, November 14, 2024, at 10 a.m. (PST) for the following purposes: 1. Financial Statements : to receive the financial statements of the Company for its fiscal year ended April 30, 2024, together with the report of the auditors thereon; 2. Board Size : to set the number of directors at four persons; 3. Election of Directors : to elect directors of the Company for the ensuing year as set forth in the Company's management information circular relating to the Meeting (the Information Circular ); 4. Appointment of Auditors: to appoint Grant Thornton LLP as auditors of the Company for the ensuing year and to authorize the directors to fix their remuneration; and 5. Other Business : to transact such other business as may properly come before the Meeting or any adjournment(s) or postponement(s) thereof. Registered shareholders and duly appointed proxyholders can attend the Meeting by logging onto https://meetnow.global/MCLVFHX . Following the instructions set forth in the accompanying Information Circular under the heading entitled “Voting of Proxies”, shareholders will be able to attend the Meeting live, participate, submit questions and vote their shares while the Meeting is being held. The Company’s board of directors requests that all registered shareholders who will not be attending the Meeting read, date, and sign the accompanying proxy and deliver it to Computershare Trust Company of Canada (“ Computershare ”). If a registered shareholder does not deliver a proxy to Computershare, 8 th Floor, 100 University Avenue, Toronto, Ontario M5J 2Y1, Attention: Proxy Unit, by fax at 1-866-249-7775 (in North America) or 1-416-263-9524 (outside North America), or by internet at www.investorvote.com by 10 a.m. (PST) on Tuesday, November 12, 2024 (or before 48 hours, excluding Saturdays, Sundays and holidays before any adjournment or postponement of the meeting at which the proxy is to be used), then the shareholder will not be entitled to vote at the Meeting by proxy, subject to the discretion of the Chair of the Meeting to waive or extend the proxy cut-off without notice. Only shareholders of record at the close of business on October 15, 2024, will be entitled to vote at the Meeting. If you are a non-registered shareholder of the Company, please complete and return the materials in accordance with the instructions set forth in the accompanying Information Circular. DATED the 14 th day of October 2024. ON BEHALF OF THE BOARD OF IMMUNOPRECISE ANTIBODIES LTD. “Jennifer L. Bath” Jennifer L. Bath President and Chief Executive Officer, and Director IMMUNOPRECISE ANTIBODIES LTD. Unit 3204 – 4464 Markham Street, Victoria, BC V8Z 7X8 MANAGEMENT INFORMATION CIRCULAR October 14, 2024 INTRODUCTION This management information circular (this “ Information Circular ”) accompanies the Notice of Ann

View Full Filing

View this 6-K filing on SEC EDGAR